Current version snapshot

FDA-approved↗↗↗↗Metabolic↗

Current · version 4: Semaglutide↗

Related names recorded in this version: Wegovy, Ozempic, Rybelsus↗

A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.↗↗↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked the Wegovy label and the Drugs@FDA approval records, and added FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026) and its April 2026 503B proposal. An August 2026 Ozempic supplement changed carton labeling only and is not reflected. 1410

What this version reported

The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.↗↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗↗

Reader guide in this version

Key takeaway

Semaglutide is a lab-made version of GLP-1, a gut hormone that helps regulate appetite, and is the active ingredient in Ozempic, Rybelsus and Wegovy.1,4,5,6 It is FDA-approved. The current Wegovy label covers long-term weight reduction, lowering the risk of major cardiovascular events in adults with heart disease and obesity or overweight, and a liver disease called MASH under accelerated approval.1 Those approvals rest on large randomized trials, including a cardiovascular trial of 17,604 adults described in the label.1 FDA says compounded and other unapproved semaglutide products are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before they are marketed.10

At a glance

What it is
A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1
FDA status
FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.1,4,5,6
Human evidence
Large randomized, placebo-controlled trials described in the Wegovy label, covering cardiovascular events, weight and MASH.1
Evidence strength
Large randomized human trials

What is semaglutide?

Semaglutide is a lab-made peptide that mimics GLP-1, a hormone released by the gut. The Wegovy label describes it as a GLP-1 analogue with 94% sequence similarity to human GLP-1.1

Drugs@FDA lists it as the active ingredient of three Novo Nordisk brands: Ozempic, Rybelsus and Wegovy.4,5,6

How does semaglutide work?

The label states that semaglutide binds to and activates the GLP-1 receptor, the target of the natural hormone, and that GLP-1 is a physiological regulator of appetite and calorie intake.1

The label also states that the exact mechanism behind its cardiovascular risk reduction has not been established, and that its mechanism in MASH is not fully understood.1

What do human studies show?

The Wegovy label describes the trials behind its approved uses. In the cardiovascular trial, 17,604 adults with established heart or blood-vessel disease and obesity or overweight, but no diabetes, were randomized to Wegovy or placebo alongside standard care.1

Over a median follow-up of 41.8 months, a first major cardiovascular event (cardiovascular death, non-fatal heart attack or non-fatal stroke) occurred in 6.5% of the Wegovy group and 8% of the placebo group, according to the label.1

The label reports that 31% of the Wegovy group and 27% of the placebo group permanently stopped the study drug during that trial.1

The label also describes several randomized, placebo-controlled weight trials lasting 68 or 72 weeks, including one of 1,961 adults without type 2 diabetes, and a MASH trial whose week-72 analysis included 800 adults.1

What the evidence base contains

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.1
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.1
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is semaglutide FDA-approved?

Yes. Drugs@FDA records list these original approval dates: Ozempic on December 5, 2017, Rybelsus on September 20, 2019, and Wegovy on June 4, 2021. A further Wegovy application was approved on December 22, 2025.4,5,6,7

The Wegovy label cited here (DailyMed SPL version 19, published June 30, 2026) states that Wegovy is indicated, with a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain the reduction long term in adults with obesity, or overweight with a weight-related condition.1

The label limits some uses to specific Wegovy products, including use in children aged 12 and older with obesity.1

The label also lists noncirrhotic MASH with moderate to advanced liver fibrosis in adults. It states that this indication was granted under accelerated approval and that continued approval may depend on a confirmatory trial.1

On March 19, 2026, FDA announced approval of Wegovy HD for weight reduction and long-term maintenance in certain adults.2

The label carries a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it causes such tumors, including medullary thyroid carcinoma, in humans. The label states that Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.1

Other warnings in the label cover acute pancreatitis, gallbladder disease, low blood sugar, kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions, diabetic eye complications in people with type 2 diabetes, increased heart rate and aspiration during anesthesia or deep sedation.1

In January 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove a warning about suicidal thoughts and behavior from their labels, after its review found no increased risk with GLP-1 medicines.8

FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are marketed. Its page on unapproved GLP-1 drugs, current as of October 1, 2026, says some compounders sell salt forms such as semaglutide sodium and semaglutide acetate, which are different active ingredients from those in the approved drugs, and that FDA is not aware of any lawful basis for compounding with them.10

The same page reports 990 adverse-event reports associated with compounded semaglutide received as of May 31, 2026, and describes counterfeit Ozempic and products falsely labeled as being for research purposes or not for human consumption.10

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities, saying it found no clinical need for them to compound these drugs from bulk substances. FDA invited comments through June 29, 2026.9

Timeline

  1. FDA approves Ozempic, the first semaglutide product, according to Drugs@FDA.4
  2. FDA approves Rybelsus, according to Drugs@FDA.5
  3. FDA approves Wegovy, according to Drugs@FDA.6
  4. FDA approves a further Wegovy application, according to Drugs@FDA.7
  5. FDA asks the makers of Saxenda, Wegovy and Zepbound to remove a suicidal thoughts and behavior warning from their labels.8
  6. FDA announces approval of Wegovy HD.2
  7. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.9
  8. DailyMed publishes the Wegovy label version cited on this page.1
  9. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.10

What is still unknown?

Whether the cardiovascular benefit applies to lower-risk groups: the label’s trial enrolled only adults aged 45 or older with established cardiovascular disease and no diabetes.1

Whether the MASH indication will be confirmed: the label says continued approval for that use may depend on a confirmatory trial.1

Whether semaglutide causes thyroid C-cell tumors in humans, which the label says has not been determined.1

What is in compounded, counterfeit or so-called research products, which FDA says it does not review before they reach the market.10

Whether FDA will finalize its April 2026 proposal on the 503B bulks list, which remained a proposal in the sources reviewed through November 14, 2026.9

Sources for this version

  1. 1
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    FDA approves higher-dose semaglutide ↗

    U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

  3. 3
    Semaglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026

  4. 4
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Drugs@FDA application NDA218316 · original submission status AP · 2025-12-22 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  8. 8
    FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  9. 9
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  10. 10
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026